United States Gene Panel Market to Grow at 19.6% CAGR, Driven by Genetic Testing, Precision Medicine & Healthcare Digitization

Leander, Texas, United States - Nov.19.2025
As per DataM intelligence research report" Global Gene Panel market to grow at a CAGR of 19.6% during the forecast period 2024 - 2031.". Precision diagnostics and targeted therapies are fueling adoption of multi-gene panels in clinical oncology.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/gene-panel-market?sp

United States: Recent Industry Developments

✅ In November 2025, Invitae launched expanded gene panel tests for hereditary cancer and rare disease diagnostics, offering comprehensive coverage and faster turnaround times. The solutions enable early detection and personalized care. This development strengthens Invitae's leadership in U.S. genetic testing.

✅ In October 2025, Thermo Fisher Scientific introduced next-generation gene panels for pharmacogenomics and clinical research, integrating high-throughput sequencing and advanced data analytics. The platforms enhance accuracy and efficiency. This reinforces Thermo Fisher's presence in precision medicine.

✅ In September 2025, Guardant Health expanded its liquid biopsy gene panel offerings for oncology, enabling non-invasive detection of actionable mutations. The panels improve patient stratification and treatment decisions. This positions Guardant Health as a key innovator in U.S. molecular diagnostics.

✅ In August 2025, Agilent Technologies launched customizable gene panels for disease research and biomarker discovery, supporting scalable genomic analysis. The solutions streamline workflows and improve reproducibility. This strengthens Agilent's footprint in advanced genomic testing.

Japan: Recent Industry Developments

✅ In November 2025, Fujirebio introduced comprehensive gene panels for oncology and inherited disorders, enabling precise molecular diagnostics. The tests support early detection and tailored therapies. This development reinforces Fujirebio's leadership in Japan's genetic testing sector.

✅ In October 2025, SRL, Inc. launched next-generation gene panels for rare disease and cancer profiling, integrating high-throughput sequencing for accurate results. The panels enhance clinical decision-making. This positions SRL as a key player in Japan's precision diagnostics market.

✅ In September 2025, Sysmex Corporation expanded its gene panel offerings for hematology and oncology applications, providing rapid and reliable mutation detection. The technology supports targeted treatment strategies. This strengthens Sysmex's presence in Japan's molecular diagnostics industry.

✅ In August 2025, Takara Bio launched customizable gene panels for research and clinical applications, enhancing coverage of clinically relevant genes. The solutions improve workflow efficiency and data quality. This reinforces Takara Bio's role in advanced genomic testing in Japan.

Gene Panel Market: Drivers

The gene panel market is experiencing rapid growth as healthcare providers increasingly adopt targeted genetic testing for precision medicine, disease diagnosis, and risk assessment. Gene panels allow simultaneous analysis of multiple genes associated with specific conditions, such as cancer, cardiovascular diseases, and inherited disorders, enabling faster and more accurate clinical decision-making. Rising demand for early detection, personalized treatment plans, and preventive healthcare is driving adoption across hospitals, diagnostic laboratories, and research institutions. Technological advancements in next-generation sequencing, bioinformatics, and assay design are enhancing the sensitivity, accuracy, and throughput of gene panel testing. Additionally, increasing awareness among patients and clinicians about genetic testing benefits is further fueling market expansion.

Expanding applications in oncology, reproductive health, rare diseases, and pharmacogenomics are broadening the scope and utility of gene panels in modern medicine. Collaborations between biotech companies, academic research centers, and diagnostic providers are accelerating development of comprehensive and condition-specific panels. Integration with electronic health records and AI-driven data analysis is improving interpretation and clinical relevance of results. Growing emphasis on cost-effective, non-invasive, and rapid diagnostic solutions is driving market adoption globally. With continuous innovation and rising focus on personalized healthcare, the gene panel market is poised for substantial growth in the coming years.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gene-panel-market?sp

Gene Panel Market: Major Players

Illumina, Inc, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI (China), Eurofins Scientific, Novogene Corporation (China), F. Hoffmann-La Roche AG, Integrated DNA Technologies, Genewiz, Inc.

Segment Covered in the Gene Panel Market:

By Product & Service
Test kits dominate with 58% share, driven by widespread adoption in clinical diagnostics, oncology screening, and hereditary disease testing. Their ease of use and rapid turnaround make them preferred across hospitals and labs. Testing services account for 42%, supported by rising outsourcing of genetic analysis to specialized centers. Growth is propelled by expanding precision medicine programs and demand for expert genomic interpretation.

By Technique
Hybridization-based approaches lead with 54% share, valued for their high accuracy, broad target coverage, and suitability for complex genomic profiling. These methods remain widely used in oncology and rare disease diagnostics. Amplicon-based approaches hold 46%, supported by their cost-effectiveness, speed, and suitability for small panel designs. Their adoption grows steadily with expanding use in targeted sequencing workflows.

By Design
Predesigned gene panels hold 63% share, driven by their standardized content, clinical validation, and widespread use in routine testing. They support cancer diagnostics, hereditary testing, and pharmacogenomics. Customized gene panels represent 37%, expanding rapidly as researchers and clinicians demand tailored solutions for specific mutations, diseases, or regional genetic diversity. Precision medicine initiatives continue accelerating this customization trend.

By Application
Cancer risk assessment leads with 41% share, driven by rising prevalence of hereditary cancers and increasing adoption of multi-gene testing. Diagnosis of congenital diseases holds 27%, supported by early genetic screening and improved neonatal diagnostics. Pharmacogenetics accounts for 22%, gaining traction as drug-response profiling becomes essential in treatment planning. Other applications represent 10%, including cardiovascular, metabolic, and neurological genetic testing.

By End User
Hospital and diagnostic laboratories dominate with 49% share, driven by high test volumes, integration of NGS-based diagnostics, and expansion of oncology screening programs. Research and academic institutes account for 30%, utilizing gene panels for disease studies, biomarker discovery, and functional genomics. Pharmaceutical and biotechnology companies hold 21%, leveraging panels in drug development, stratified trials, and companion diagnostics. All segments benefit from growing genomic adoption.

Regional Analysis

North America - 37% Share
North America leads with 37%, supported by advanced genomic testing infrastructure, reimbursement frameworks, and high adoption of precision medicine. The U.S. dominates due to extensive cancer screening programs and strong clinical lab networks. Research investments continue to accelerate panel development and clinical use. Integration with NGS platforms boosts regional growth.

Europe - 30% Share
Europe holds 30%, driven by strong regulatory support for genetic testing, widespread hereditary disease screening, and advancements in oncology diagnostics. Germany, the U.K., France, and the Nordics lead adoption. Increasing pharmacogenomic utilization strengthens demand. Public health initiatives continue expanding accessibility across the region.

Asia Pacific - 26% Share
Asia Pacific captures 26%, supported by expanding healthcare infrastructure, rising genetic testing awareness, and large patient populations. China, Japan, South Korea, and India drive rapid adoption in oncology and congenital disease diagnostics. Government genomics initiatives accelerate growth. Affordable panel tests boost market penetration.

Latin America - 3% Share
Latin America holds 3%, with Brazil and Mexico driving adoption mainly in oncology and hereditary disease testing. Limited healthcare access slows widespread uptake, yet private sector diagnostics continue growing. Emerging research programs support modest panel usage. Market expansion remains steady.

Middle East - 2% Share
The Middle East accounts for 2%, driven by increasing investment in genomic medicine, especially in GCC countries. Congenital disease testing is a major application due to high genetic disorder prevalence. Diagnostic lab modernization supports gradual adoption. Awareness and infrastructure improvements fuel early-stage growth.

Africa - 2% Share
Africa holds 2%, with adoption primarily in South Africa and gradually expanding across Kenya, Nigeria, and Egypt. Use cases include infectious disease genomics and rare disease diagnostics. Limited resources constrain growth, but international collaborations boost accessibility. Awareness and testing capacity continue to improve gradually.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=gene-panel-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.